Baseline Splenic Volume as a Prognostic Biomarker of FOLFIRI Efficacy and a Surrogate Marker of MDSC Accumulation in Metastatic Colorectal Carcinoma.
Julie NiogretEmeric LimagneMarion ThibaudinJulie BlancAurelie BertautKarine Le MalicotYves RinaldiFrançois-Xavier Caroli-BoscFranck AudemarSuzanne NguyenCorinne SardaCatherine Lombard-BohasChristophe LocherMiguel CarreiroJean-Louis LegouxPierre-Luc EtienneMathieu BaconnierMarc PorneufThomas AparicioFrançois GhiringhelliPublished in: Cancers (2020)
Baseline splenomegaly is a prognostic biomarker in patients with mCRC treated with FOLFIRI and bevacizumab, and a surrogate marker of MDSC accumulation.